Abstract
In the last few years, bench and clinical studies led to significant new insight into how cyclic adenosine monophosphate (cAMP) signaling, the molecular pathway that had been identified in the early 2000s as the one involved in most benign cortisol-producing adrenal hyperplasias, affects adrenocortical growth and development, as well as tumor formation. A major discovery was the identification of tissue-specific pluripotential cells (TSPCs) as the culprit behind tumor formation not only in the adrenal, but also in bone. Discoveries in animal studies complemented a number of clinical observations in patients. Gene identification continued in parallel with mouse and other studies on the cAMP signaling and other pathways.
Published by Elsevier Ireland Ltd.
MeSH terms
-
Adrenal Cortex / metabolism
-
Adrenal Cortex Neoplasms / genetics
-
Adrenal Cortex Neoplasms / metabolism*
-
Adrenal Hyperplasia, Congenital / genetics
-
Adrenal Hyperplasia, Congenital / metabolism*
-
Animals
-
Cyclic AMP / genetics
-
Cyclic AMP / metabolism*
-
Cyclic AMP-Dependent Protein Kinase Catalytic Subunits / genetics
-
Cyclic AMP-Dependent Protein Kinase RIalpha Subunit / genetics
-
Cyclic AMP-Dependent Protein Kinase RIalpha Subunit / metabolism
-
Cyclic AMP-Dependent Protein Kinases / genetics
-
Cyclic AMP-Dependent Protein Kinases / metabolism*
-
Cyclooxygenase 2 / genetics
-
Cyclooxygenase 2 / metabolism
-
Dinoprostone / genetics
-
Dinoprostone / metabolism
-
Humans
-
Mice
-
Pluripotent Stem Cells
-
Signal Transduction
Substances
-
Cyclic AMP-Dependent Protein Kinase RIalpha Subunit
-
PRKAR1A protein, human
-
Prkar1a protein, mouse
-
Cyclic AMP
-
Ptgs2 protein, mouse
-
Cyclooxygenase 2
-
Cyclic AMP-Dependent Protein Kinase Catalytic Subunits
-
Cyclic AMP-Dependent Protein Kinases
-
Prkaca protein, mouse
-
Dinoprostone